AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is …
Over the last 12 months, insiders at AbCellera Biologics Inc. have bought $739,977 and sold $0 worth of AbCellera Biologics Inc. stock.
On average, over the past 5 years, insiders at AbCellera Biologics Inc. have bought $37.55M and sold $394.03M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thermopylae Holdings Ltd. (10 percent owner) — $739,977.
The last purchase of 283,516 shares for transaction amount of $739,977 was made by Thermopylae Holdings Ltd. (10 percent owner) on 2024‑08‑29.
2024-08-29 | 10 percent owner | 283,516 0.0993% | $2.61 | $739,977 | +4.35% | |||
2023-11-08 | director | 10,000 0.0037% | $4.46 | $44,600 | -3.75% | |||
2023-11-06 | director | 20,000 0.0071% | $4.64 | $92,800 | -9.70% | |||
2023-09-22 | director | 20,000 0.0066% | $4.91 | $98,200 | -12.40% | |||
2023-09-12 | Chief Operating Officer | 20,000 0.007% | $5.19 | $103,800 | -14.30% | |||
2023-08-08 | director | 30,000 0.0104% | $5.90 | $177,000 | -22.03% | |||
2023-05-26 | 10 percent owner | 153,000 0.051% | $6.52 | $997,728 | -26.32% | |||
2023-05-26 | Chief Financial Officer | 14,500 0.0051% | $6.85 | $99,325 | -26.32% | |||
2022-12-16 | director | 85,102 0.0295% | $10.10 | $859,249 | -33.50% | |||
2022-08-19 | 10 percent owner | 200,000 0.0702% | $11.46 | $2.29M | -19.58% | |||
2022-06-14 | 10 percent owner | 9,173 0.0029% | $8.05 | $73,842 | +16.48% | |||
2022-06-13 | 10 percent owner | 54,915 0.0189% | $8.03 | $441,066 | +25.00% | |||
2022-06-06 | 10 percent owner | 64,545 0.0222% | $7.50 | $483,965 | +33.64% | |||
2022-05-16 | Chief Operating Officer | 200,000 0.057% | $6.34 | $1.27M | +31.24% | |||
2022-05-13 | 10 percent owner | 300,000 0.1057% | $7.26 | $2.18M | +41.77% | |||
2022-05-12 | 10 percent owner | 1.41M 0.4723% | $6.41 | $9.02M | +52.76% | |||
2022-05-12 | Chief Financial Officer | 85,000 0.0258% | $5.79 | $492,150 | +52.76% | |||
2022-03-04 | director | 10,000 0.0035% | $8.54 | $85,400 | +20.22% | |||
2022-03-01 | director | 20,000 0.0071% | $9.05 | $181,000 | +13.38% | |||
2022-02-28 | Chief Operating Officer | 230,789 0.0808% | $8.66 | $2M | +17.68% |
Thermopylae Holdings Ltd. | 10 percent owner | 56086009 18.9886% | $2.77 | 10 | 1 | +6.49% |
THIEL PETER | director | 10179880 3.4465% | $2.77 | 1 | 0 | <0.0001% |
Lecault Veronique | Chief Operating Officer | 2040122 0.6907% | $2.77 | 4 | 1 | <0.0001% |
Hayden Michael R | director | 1323397 0.4481% | $2.77 | 3 | 1 | <0.0001% |
Booth Andrew | Chief Financial Officer | 153000 0.0518% | $2.77 | 3 | 1 | <0.0001% |
Baker Bros Advisors LP | $124.69M | 9.36 | 27.53M | +20.15% | +$20.91M | 0.9 | |
Baillie Gifford Co | $105.01M | 7.88 | 23.18M | -3.6% | -$3.92M | 0.08 | |
Voya Investment Management LLC | $48.16M | 3.62 | 10.63M | +0.07% | +$36,008.97 | 0.05 | |
Capital World Investors | $37.83M | 2.84 | 8.35M | 0% | +$0 | 0.01 | |
Credit Suisse | $20.6M | 1.55 | 4.55M | -0.68% | -$140,135.55 | 0.02 |